Navigation Links
Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
Date:7/1/2008

bis, and the development and commercialization of the Ibis T5000 Biosensor System and Ibis' technology. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, and its quarterly report on Form 10-Q for the quarter ended March 31, 2008, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Abbott to Present at Goldman Sachs Global Healthcare Conference
2. Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System
3. Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder
4. Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline
5. Abbott Announces Labs Are Vital(TM) Facebook Scholarship Contest Winners
6. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
7. Smiths Medical to Promote and Distribute Abbotts FreeStyle Navigator Continuous Glucose Monitoring System
8. Abbott to Present at Cowen and Company Health Care Conference
9. Abbott to Present at Lehman Brothers Healthcare Conference
10. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
11. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... TX (PRWEB) January 15, 2014 More ... disease, and about 1 in 3 seniors will die ... source ). These jaw-dropping figures have shocked many Americans ... and, hopefully, help prevent these tragic age-related cognitive disorders. ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... a leading clinical stage biotechnology company with offices ... proprietary stem cell and tissue engineering based therapies, ... Cooperative Research and Development Agreement (CRADA) with the ... at Fort Sam Houston, Texas. The 3-year CRADA, ...
... PARK, Md., June 6, 2011 CosmosID™, a ... (TAP) incubator developing comprehensive pathogen identification technologies, ... life sciences company category during the 2011 Maryland ... (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO ) In ...
... June 6, 2011 Celtaxsys, Inc., a private biopharmaceutical company ... sciences industry veteran, H. Daniel Perez, M.D., to its Board ... Dr. Perez has joined the Celtaxsys team," says Dr. Michael ... "He brings more than 25 years of high level pharmaceutical ...
Cached Biology Technology:Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 2Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 2Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 4Dr. H. Daniel Perez Joins Celtaxsys Board of Directors 2
(Date:7/10/2014)... 10 July 2014 Amyloid diseases, such as ... spongiform encephalopathies, all share the common trait that ... plaques. Yet in vitro studies have found that ... themselves are very toxic. New evidence using two-dimensional ... structure during the amylin aggregation pathway that may ...
(Date:7/10/2014)... 10,2014 For children and teens living with a ... contribute to decreased quality of life, reports a study ... Behavioral Pediatrics , the official journal of the ... The journal is published by Lippincott Williams & ... . , "Self-competence may function as a protective factor ...
(Date:7/10/2014)... natural-color satellite image was collected by the Moderate Resolution ... 10, 2014. Each hot spot, which appears as a ... on the MODIS instrument recognized temperatures higher than background. ... image, such hot spots are diagnostic for fire. ... little danger coming directly from the fires, although the ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2For children with pacemakers, 'self-competence' affects quality of life 2
... appointment of Esin Gulari, dean of the College of Engineering ... Science Board (NSB). President George W. Bush nominated Gulari for ... is a tremendous honor for me as a scientist and ... in a unique position to make contributions on a national ...
... 3, 2008 Case Western Reserve University School of Medicine ... The National Children,s Study, the National Institutes of Health,s comprehensive ... children,s health. At a briefing today, NIH ... one of 36 new and existing study centers which would ...
... observance of Nuclear Medicine Week (October 5 to 11) ... today a new fact sheet highlighting recent developments in ... in which breast cancer is diagnosed and treated. ... painless imaging tool for diagnosing and treating breast cancer. ...
Cached Biology News:US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board 2NIH selects Case Western Reserve University to participate in National Children's Study 2SNM releases new fact sheet on breast cancer and molecular imaging 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Normal serum collected from healthy Kunming mice....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: